Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | IMGO | Common Stock | Options Exercise | $13.7K | +6.5K | +5.46% | $2.10* | 126K | Feb 1, 2022 | Direct | F1 |
transaction | IMGO | Common Stock | Sale | -$113K | -5.75K | -4.58% | $19.69 | 120K | Feb 1, 2022 | Direct | F1, F2 |
transaction | IMGO | Common Stock | Sale | -$15.2K | -750 | -0.63% | $20.26 | 119K | Feb 1, 2022 | Direct | F1, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | IMGO | Stock Option (Right to Buy) | Options Exercise | $0 | -6.5K | -10.92% | $0.00 | 53K | Feb 1, 2022 | Common Stock | 6.5K | $2.10 | Direct | F1, F4 |
Id | Content |
---|---|
F1 | Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. |
F2 | The transaction was executed in multiple trades in prices ranging from $19.21 to $20.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
F3 | The transaction was executed in multiple trades in prices ranging from $20.22 to $20.30, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
F4 | The Option vests with respect to 25% of the shares subject thereto on July 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Senior Vice President, Non-Clinical and CMC